tiprankstipranks
Trending News
More News >
Enzo Biochem (ENZB)
OTHER OTC:ENZB
Advertisement

Enzo Biochem (ENZB) AI Stock Analysis

Compare
189 Followers

Top Page

ENZB

Enzo Biochem

(OTC:ENZB)

Rating:54Neutral
Price Target:
$0.50
▼(-26.47%Downside)
Enzo Biochem's overall stock score is primarily impacted by its challenging financial performance and valuation issues due to declining revenues and profitability. However, the upcoming merger with Battery Ventures provides a positive outlook, offering a significant premium and a strategic path forward. Technical analysis shows potential short-term gains but also warns of overbought conditions.

Enzo Biochem (ENZB) vs. SPDR S&P 500 ETF (SPY)

Enzo Biochem Business Overview & Revenue Model

Company DescriptionEnzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing 'STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in New York, New York.
How the Company Makes MoneyEnzo Biochem generates revenue primarily through its two operating segments. Enzo Clinical Labs earns money by providing diagnostic and clinical laboratory testing services to physicians, medical centers, and other healthcare providers. This includes routine blood tests, molecular diagnostics, and specialized testing services. Enzo Life Sciences generates revenue by selling a wide range of life sciences products, including reagents, assays, and kits to academic institutions, biopharmaceutical companies, and laboratories worldwide. The company also benefits from partnerships and licensing agreements that leverage its proprietary technologies and intellectual property, contributing to its earnings.

Enzo Biochem Financial Statement Overview

Summary
Enzo Biochem's financial performance is under pressure due to declining revenues and losses, as indicated by the income statement. The balance sheet shows moderate stability with low leverage, but the cash flow analysis highlights significant challenges with negative free cash flow and operating cash flow. Overall, the company is facing substantial financial hurdles, risking long-term sustainability without a turnaround.
Income Statement
40
Negative
Enzo Biochem's income statement reveals a challenging financial position with declining revenues and persistent losses. The company experienced a significant revenue drop from previous years, coupled with negative net income and EBIT margins in TTM (Trailing-Twelve-Months). The gross profit margin stands at 43.75%, indicating some cost management effectiveness, but the negative net profit margin of -76.75% highlights profitability issues.
Balance Sheet
55
Neutral
The balance sheet shows moderate stability with a debt-to-equity ratio of 0.07, reflecting low leverage. However, the declining stockholders' equity and total assets suggest a shrinking balance sheet. The equity ratio of 68.34% indicates that a significant portion of assets is financed by equity, which is a positive sign of financial health.
Cash Flow
35
Negative
Cash flow analysis indicates significant challenges, with a negative free cash flow and operating cash flow in TTM. The company showed a negative free cash flow growth rate, reflecting cash generation issues. The operating cash flow to net income ratio is unfavorable, indicating that operations are not generating enough cash to cover losses.
BreakdownSep 2024Sep 2023Sep 2022Sep 2021Sep 2020
Income Statement
Total Revenue31.91M31.06M107.07M117.73M76.02M
Gross Profit14.63M11.57M41.97M53.58M23.77M
EBITDA-8.35M-20.94M-15.01M3.35M-27.59M
Net Income-26.08M20.29M-22.58M3.42M-33.89M
Balance Sheet
Total Assets85.76M121.88M95.86M113.69M112.54M
Cash, Cash Equivalents and Short-Term Investments52.37M82.37M21.60M43.50M47.87M
Total Debt3.51M7.00M20.59M22.68M32.79M
Total Liabilities29.65M43.42M41.40M45.10M54.16M
Stockholders Equity56.11M78.46M54.46M68.59M58.38M
Cash Flow
Free Cash Flow-26.80M-39.74M-20.06M-4.05M-19.35M
Operating Cash Flow-26.26M-36.98M-16.59M387.00K-17.18M
Investing Cash Flow-545.00K98.98M25.22M-34.50M-2.17M
Financing Cash Flow-4.19M-1.13M-241.00K-242.00K7.00M

Enzo Biochem Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.68
Price Trends
50DMA
0.62
Positive
100DMA
0.52
Positive
200DMA
0.68
Negative
Market Momentum
MACD
0.02
Positive
RSI
68.22
Neutral
STOCH
16.67
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENZB, the sentiment is Positive. The current price of 0.68 is above the 20-day moving average (MA) of 0.68, above the 50-day MA of 0.62, and below the 200-day MA of 0.68, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 68.22 is Neutral, neither overbought nor oversold. The STOCH value of 16.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ENZB.

Enzo Biochem Risk Analysis

Enzo Biochem disclosed 30 risk factors in its most recent earnings report. Enzo Biochem reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Enzo Biochem Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
57
Neutral
$268.10M-414.88%-65.96%40.80%
56
Neutral
$33.46M-104.33%-5.50%56.57%
54
Neutral
$35.68M-13.95%
52
Neutral
$7.62B0.05-63.03%2.44%16.33%0.31%
36
Underperform
$27.90M-60.35%53.95%
35
Underperform
$23.36M-246.21%44.38%
30
Underperform
$49.18M-2880.11%31.09%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ENZB
Enzo Biochem
0.68
-0.37
-35.24%
IGC
IGC Pharma
0.37
-0.08
-17.78%
TVRD
Tvardi Therapeutics
27.29
13.88
103.50%
ENLV
Enlivex
1.14
-0.22
-16.18%
BCAB
BioAtla
0.40
-1.22
-75.31%
NRSN
Neurosense Therapeutics Ltd.
2.03
1.22
150.62%

Enzo Biochem Corporate Events

Delistings and Listing ChangesM&A Transactions
Enzo Biochem Announces Merger with Battery Ventures
Positive
Jun 24, 2025

On June 23, 2025, Enzo Biochem, Inc. entered into a merger agreement to be acquired by Battery Ventures for $0.70 per share in cash, totaling approximately $37 million. This transaction, which follows a strategic review by Enzo’s Board, represents a 75% premium to the company’s closing price on April 22, 2025. The merger is subject to customary closing conditions, including shareholder approval, and is expected to close in the third quarter of 2025. Upon completion, Enzo will become a privately held company, and its shares will no longer be publicly traded. The acquisition is seen as a strategic move to maximize shareholder value.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 09, 2025